课题基金 / 基金详情

CLINICAL AND THERAPEUTIC STUDIES OF HUMAN FILARIASIS

CLINICAL AND THERAPEUTIC STUDIES OF HUMAN FILARIASIS
人类丝虫病的临床和治疗研究
批准号:
2566774
负责人:
T B NUTMAN
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

T B NUTMAN的其他基金

相似基金

相关文献

中文摘要
翻译
最近的临床和流行病学研究确定了
英文摘要
Recent clinical and epidemiological studies have defined the presence of individuals with natural immunity to infection with filarial parasites. Some infected individuals may remain microfilaremic over long periods of time, without developing overt lymphatic pathology, but others develop such pathology that can develop either in the setting of persistent microfilaremia or after microfilaremia has cleared. The underlying mechanisms for these differences are being assessed at the genetic and immunologic level. PCR-based amplifications of parasite DNA in skin snips from patients with onchocerciasis have increased diagnostic sensitivity and specificity, and the assays have been configured into an ELISA format that is field applicable. Efforts to acheive detection DNA in lymphatic filariasis and in loiasis have also been developed and placed into field applicable formats. Adverse reactions associated with treatment of onchocerciasis and lymphatic filariasis have been shown to be mediated by proinflammatory cytokines (IL-6 and TNF-a), the growth factors IL-5 and GM-CSF, and the eosinophil chemoattractant, RANTES. Albendazole, an anthelmintic drug with primarily macrofilaricidal effects, has been shown capable of successfully treating loiasis refractory to standard therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MOLECULAR DEFINITION OF FILARIAL ANTIGENS
IMMUNOREGULATION AND IMMUNE RECOGNITION IN FILARIASIS AND NON-FILARIAL DISEASES
IMMUNOREGULATION AND IMMUNE RECOGNITION IN FILARIASIS AND NON-FILARIAL DISEASES
MOLECULAR DEFINITION OF FILARIAL ANTIGENS
海外基金